Data for this review were identified by searches of PubMed and references from relevant articles, as well as the personal files of the authors. Search terms included “Helicobacter pylori”, “therapy”, “treatment options”, “antibiotic resistance”, and “clinical implications”. Searches using the names of prominent scientists in the field were also done. The selection of papers was not restricted by language. The final search date was December, 2005.
ReviewHelicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications
Introduction
In 1983, Warren and Marshall were the first to report the successful cultivation of the human pathogen Helicobacter pylori from gastric biopsy samples.1, 2 By self-ingestion experiments, they showed that this bacterium indeed caused gastroduodenal disorders, thereby fulfilling Koch's postulates.3, 4 This important discovery, rewarded with the 2005 Nobel prize for physiology or medicine, has changed peptic ulcer disease from a chronic, relapsing disease of uncertain cause into a curable infectious disease. Today, H pylori is accepted as the causative agent of acute and chronic gastritis, and a major predisposing factor for peptic ulcer disease, gastric carcinoma, and gastric lymphoma (figure 1).5, 6
Infection with H pylori occurs worldwide, but there are substantial differences in the prevalence of the infection both within and between countries. In industrialised countries, the overall carriage rate of H pylori infection in middle-aged adults is 20–50%, compared with 80% or more in many developing countries.7, 8 Acquisition of H pylori predominantly occurs during childhood, and once acquired, the infection persists throughout life unless specifically treated. In developing countries the carriage rate of H pylori remains relatively stable, but in the industrialised world these values have substantially decreased over recent decades,9 probably as a result of improved hygiene and sanitation, especially during childhood,9 and active elimination of carriership via antimicrobial treatment.
H pylori-associated disorders usually regress or heal completely after successful treatment of H pylori infection with antimicrobials. However, the available antimicrobial therapies for H pylori infection have many shortcomings—eg, side-effects, the need for combination therapy, and limited efficacy, in particular because of the development of antimicrobial resistance. The continuous increase in the prevalence of antimicrobial resistance in H pylori, together with the lack of forthcoming novel treatment options, already negatively affects eradication of H pylori infection, and is predicted to lead to serious problems for treatment of H pylori-associated disorders in the near future.
Section snippets
Diagnosis of H pylori infection
H pylori infection can be diagnosed by a variety of invasive and non-invasive tests.10 Invasive tests are based on gastric samples, usually mucosal biopsies, which can be screened by rapid urease test, histology, or culture.10 Non-invasive tests require alternative clinical specimens—eg, blood, breath, faeces, urine, or saliva. These samples can be screened by serology, urea breath test, or stool antigen test.10 The choice of a specific test depends on several factors, including gastric
Treatment of H pylori infections
Peptic ulcer disease and other H pylori-associated disorders usually regress or even heal completely after treatment of the H pylori infection.18, 19 In vitro, H pylori is susceptible to most antimicrobials20 but in vivo only a few antimicrobials can be used to cure infected patients.21 The lack of activity in vivo is because of a combination of factors—eg, inability of drugs to achieve appropriate levels in the gastric mucus layer,22, 23 inactivation of drugs at low pH,24, 25 and the slow
Prevalence of antimicrobial resistance
Resistance to nitroimidazoles is the most common form of antimicrobial resistance in H pylori. Metronidazole and tinidazole are the most frequently used nitroimidazoles for treatment of H pylori infection, and there seems to be substantial cross-resistance between these nitroimidazoles.45 In industrialised countries, about 35% of the H pylori strains are resistant to nitroimidazoles (minimum inhibitory concentration [MIC] ≥8 mg/L; susceptibility breakpoint),46, 47 whereas in developing
Clinical effect of antibiotic resistance
Numerous studies have shown that antibiotic resistance substantially impairs the efficacy of anti-H pylori therapy.64, 65, 66, 67, 68, 69 Nevertheless, the clinical relevance of antibiotic resistance in H pylori-associated diseases is still challenged. The extent to which antibiotic resistance reduces the success rates of H pylori treatment depends on a variety of factors—eg, the components used in therapy, the dose of the antimicrobial drugs, the duration of the therapy, and the level of
Antibiotic activity and mechanisms of resistance
In view of the large number of individuals colonised with H pylori, the proportion of individuals who develop disease, and the relative difficulty to treat the infection, it is not surprising that a lot of effort has been spent on understanding the mechanisms of antibiotic resistance. The obtained knowledge (figure 3) could allow for rapid testing of resistance and can provide clues to decrease the spread of antibiotic resistance. In many bacteria, antibiotic resistance mechanisms are located
Detection of antibiotic resistance
Numerous techniques have been developed to detect antibiotic resistance in H pylori. These methods can be divided in culture and nucleic acid-based assays (figure 4). Antibiotic susceptibility in H pylori is usually assessed by culture-based methods (eg, agar dilution, disc diffusion, E-test, breakpoint susceptibility testing, broth microdilution method), but since knowledge of antibiotic resistance mechanisms in H pylori is growing, several (non-)invasive nucleic acid-based tests have been
Alternative treatment options
In the past few years, much time and effort has been spent in developing alternative anti-H pylori treatments, especially via vaccine development. Prophylactic as well as therapeutic vaccination could potentially save millions of lives and reduce the costs related to the treatment of H pylori-associated diseases. Several virulence factors (eg, urease), the vacuolating toxin A (VacA), the cytotoxin-associated antigen (CagA), and the blood-group-antigen binding adhesin (BabA), in combination with
Search strategy and selection criteria
References (148)
- et al.
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration
Lancet
(1984) - et al.
Helicobacter in the developing world
Microbes Infect
(2003) - et al.
Burden of Helicobacter pylori and H pylori-related diseases in developed countries: recent developments and future implications
Microbes Infect
(2003) - et al.
Helicobacter pylori “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis
Gastroenterology
(2005) - et al.
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group
Lancet
(1995) Antibiotic resistance in Helicobacter pylori: implications for therapy
Gastroenterology
(1998)- et al.
Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori
Int J Antimicrob Agents
(2004) Bismuth therapy in gastrointestinal diseases
Gastroenterology
(1990)- et al.
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis
Am J Gastroenterol
(1999) - et al.
Antibiotic resistance problems with Helicobacter pylori
Int J Antimicrob Agents
(1999)
Metronidazole resistance in Helicobacter pylori
Int J Antimicrob Agents
Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance
FEMS Microbiol Lett
Unidentified curved bacilli on gastric epithelium in active chronic gastritis
Lancet
Attempt to fulfil Koch's postulates for pyloric Campylobacter
Med J Aust
Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH
Am J Gastroenterol
Pathogenesis of Helicobacter pylori infection
Clin Microbiol Rev
Helicobacter pylori infection
N Engl J Med
Review article: after gastritis—an imaginary journey into a helicobacter-free world
Aliment Pharmacol Ther
Helicobacter pylori. Pathology and diagnostic strategies
Am J Clin Pathol
Eradication of Helicobacter pylori in clinical situations
Clin Exp Med
The CLO test in the UK: inappropriate reading and missed results
Eur J Gastroenterol Hepatol
Is routine histological evaluation an accurate test for Helicobacter pylori infection?
Aliment Pharmacol Ther
Any role left for invasive tests? Histology in clinical practice
Gut
Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review
Aliment Pharmacol Ther
Utility of serology in determining Helicobacter pylori eradication after therapy
Can J Gastroenterol
Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment
Aliment Pharmacol Ther
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents
Antimicrob Agents Chemother
Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa
J Antimicrob Chemother
Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori
J Clin Pathol
Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents
Eur J Clin Microbiol Infect Dis
Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents
Eur J Clin Microbiol Infect Dis
Review article: the treatment of refractory Helicobacter pylori infection
Aliment Pharmacol Ther
Helicobacter pylori “rescue” therapy after failure of two eradication treatments
Helicobacter
Treatment strategies for Helicobacter pylori infection
Am Fam Physician
Treatment of Helicobacter pylori infection: a review of the world literature
Helicobacter
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori
Gut
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication
Aliment Pharmacol Ther
Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens
Can J Gastroenterol
The actions of bismuth in the treatment of Helicobacter pylori infection
Aliment Pharmacol Ther
Helicobacter pylori therapy: first-line options and rescue regimen
Dig Dis
Clinical approach to the Helicobacter pylori-positive patient
Treatment and management of Helicobacter pylori infection
Curr Gastroenterol Rep
Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report
Aliment Pharmacol Ther
Regular review: treatment of Helicobacter pylori infection
BMJ
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication
Aliment Pharmacol Ther
Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy
Aliment Pharmacol Ther
Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis
Int J Epidemiol
Treatment of Helicobacter pylori eradication failures
Curr Treat Options Gastroenterol
One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance
Aliment Pharmacol Ther
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori
Eur J Clin Microbiol Infect Dis
Cited by (249)
Prevalence of Primary Multidrug-resistant Helicobacter pylori in Children: A Systematic Review and Meta-analysis
2022, Archives of Medical ResearchEmpiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods?
2022, Revista de Gastroenterologia de MexicoDealing with MDR bacteria and biofilm in the post-antibiotic era: Application of antimicrobial peptides-based nano-formulation
2021, Materials Science and Engineering CAntibiotic Resistance of Helicobacter pylori: Mechanisms and Clinical Implications
2024, Journal of Korean Medical Science